Antiviral activity of temporin-1CEb analogues against gingival infection with herpes simplex virus type 1.

antimicrobial peptides drug-resistance gingival infection heparan sulfate herpes simplex virus temporins

Journal

Frontiers in oral health
ISSN: 2673-4842
Titre abrégé: Front Oral Health
Pays: Switzerland
ID NLM: 9918227262706676

Informations de publication

Date de publication:
2024
Historique:
received: 09 05 2024
accepted: 30 05 2024
medline: 2 7 2024
pubmed: 2 7 2024
entrez: 2 7 2024
Statut: epublish

Résumé

Oral herpes infections caused by herpes simplex virus type 1 (HSV-1) are one of the most common in the human population. Recently, they have been classified as an increasing problem in immunocompromised patients and those suffering from chronic inflammation of the oral mucosa and gums. Treatment mainly involves nucleoside analogues, such as acyclovir and its derivatives, which reduce virus replication and shedding. As drug-resistant strains of herpes emerge rapidly, there is a need for the development of novel anti-herpes agents. The aim of the study was to design an antiviral peptide, based on natural compounds, non-toxic to the host, and efficient against drug-resistant HSV-1. Here, we designed a lysine-rich derivative of amphibian temporin-1CEb conjugated to peptides penetrating the host cell membrane and examined their activity against HSV-1 infection of oral mucosa. We assessed the antiviral efficiency of the tested compound in simple 2D cell models (VeroE6 and TIGKs cells) and a 3D organotypic model of human gingiva (OTG) using titration assay, qPCR, and confocal imaging. To identify the molecular mechanism of antiviral activity, we applied the Azure A metachromatic test, and attachment assays techniques. Toxicity of the conjugates was examined using XTT and LDH assays. Our results showed that temporin-1CEb analogues significantly reduce viral replication in oral mucosa. The mechanism of peptide analogues is based on the interaction with heparan sulfate, leading to the reduce attachment of HSV-1 to the cell membrane. Moreover, temporin-1CEb conjugates effectively penetrate the gingival tissue being effective against acyclovir-resistant strains. Collectively, we showed that temporin-1CEb can be regarded as a novel, naturally derived antiviral compound for HSV-1 treatment.

Identifiants

pubmed: 38953010
doi: 10.3389/froh.2024.1430077
pmc: PMC11215077
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1430077

Informations de copyright

© 2024 Golda, Kosikowska-Adamus, Wadowska, Dobosz, Potempa and Koziel.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Auteurs

Anna Golda (A)

Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.

Paulina Kosikowska-Adamus (P)

Department of Organic Chemistry, Faculty of Chemistry, University of Gdansk, Gdansk, Poland.

Marta Wadowska (M)

Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.

Ewelina Dobosz (E)

Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.

Jan Potempa (J)

Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
Department of Oral Immunology and Infectious Diseases, University of Louisville School of Dentistry, University of Louisville, Louisville, KY, United States.

Joanna Koziel (J)

Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.

Classifications MeSH